✨
AI Summary
- Tonix Pharmaceuticals is developing TNX-4800, a monoclonal antibody for Lyme disease prevention.
- This approach bypasses traditional vaccines, targeting the OspA protein on Borrelia burgdorferi.
- The strategy aims to fill the gap left by previous vaccine withdrawals and failures.
Guests on This Episode
SL
Seth Lederman
1 podcast appearance